Prostate cancer

Tailoring treatment for metastatic hormone-sensitive prostate cancer

Earn accreditation points

Finish 5 case(s) answer 10 question(s) and Earn 1 credit.


Educational Objective: Learn how new clinical data influence the treatment choice in patients with mHSPC: which patients benefit from systemic treatment, which patients from local therapy?
Specialty: Medical oncology, urology, clinical oncology, radiation oncology
Target Audience: CME (intermediate-advanced), Residents (senior)
Latest update: November 2021

New data for patients with mHSPC are paving the way for a more personalised treatment approach. Both men with metastases at first presentation (synchronous) and patients who received local therapy before detection of metastases (metachronous) are addressed.